Baudax Bio, Inc. (BXRX)
Stock Price:
$1.08 USD
-0.14 (-11.16%)
Updated Oct 28, 2020 11:02 AM EDT - Market open
Key Info
| Market Cap |
19.75M |
| Revenue (ttm) |
349,000 |
| Net Income (ttm) |
-88.38M |
| Shares Out |
18.37M |
| EPS (ttm) |
-4.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$1.08 |
| Previous Close |
$1.21 |
| Change ($) |
-0.14 |
| Change (%) |
-11.16% |
| Day's Open |
1.15 |
| Day's Range |
1.07 - 1.15 |
| Day's Volume |
1,094,787 |
| 52-Week Range |
1.07 - 10.14 |
More Stats
| Market Cap |
19.75M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Feb 18, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.37M |
| Float |
18.03M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-4.81 |
| FCF / Share |
-1.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.92M |
| Short Ratio |
7.10 |
| Short % of Float |
10.67% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
56.60 |
| PB Ratio |
n/a |
| Revenue |
349,000 |
| Operating Income |
-38.11M |
| Net Income |
-88.38M |
| Free Cash Flow |
-28.27M |
| Net Cash |
30.13M |
| Net Cash / Share |
1.64 |
| Gross Margin |
-86.20% |
| Operating Margin |
-10,920.06% |
| Profit Margin |
-25,324.60% |
| FCF Margin |
-8,101.43% |
| ROA |
-41.69% |
| ROE |
n/a |
| ROIC |
4,009.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.67*
(799.53% upside)
Low
7.00
Current: $1.08
High
11.00
Target: 9.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -47.07 | -65.04 | -48.26 |
| Net Income | -32.56 | -73.67 | -61.08 |
| Shares Outstanding | 9.35 | 9.35 | - |
| Earnings Per Share | -3.48 | -7.88 | - |
| Operating Cash Flow | -50.04 | -59.75 | -43.27 |
| Capital Expenditures | -1.48 | -3.45 | -1.29 |
| Free Cash Flow | -51.53 | -63.20 | -44.56 |
| Cash & Equivalents | 17.74 | - | - |
| Total Debt | 0.77 | - | - |
| Net Cash / Debt | 16.97 | - | - |
| Assets | 54.21 | 35.02 | 32.76 |
| Liabilities | 70.93 | 103 | 95.22 |
| Book Value | -16.72 | -68.35 | -62.46 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Baudax Bio, Inc. |
| Country |
United States |
| Employees |
24 |
| CEO |
Gerri A. Henwood |
Stock Information
| Ticker Symbol |
BXRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BXRX |
Description
Baudax Bio, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.